Study title: Utilidad de la tizanidina. Seguimiento de un ano en el tratamiento de la espasticidad en la paralysis (The usefulness of tizanidine. A one−year follow−up of the treatment of spasticity in infantile cerebral palsy). Vásquez BA, Arellano SME, León HSR, Morales OMG. Revista de neurologia, Aug 1−15 2006, vol. 43, no. 3, p. 132−6Utilidad de la tizanidina. Seguimiento de un ano en el tratamiento de la espasticidad en la paralysis (The usefulness of tizanidine. A one−year follow−up of the treatment of spasticity in infantile cerebral palsy). Vásquez BA, Arellano SME, León HSR, Morales OMG. Revista de neurologia, Aug 1−15 2006, vol. 43, no. 3, p. 132−6
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nervous System Diseases [C10] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TINZANIDINE | |||||
| ATC code: M03B X02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: , | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |